Lupus Nephritis Clinical Trials in Nanjing, Jiangsu
8 recruitingNanjing, Jiangsu, China
Showing 1–8 of 8 trials
Recruiting
Phase 3
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
Lupus Nephritis
Novartis Pharmaceuticals462 enrolled188 locationsNCT05126277
Recruiting
Phase 2
The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment
Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)
Nanjing University School of Medicine50 enrolled1 locationNCT07340463
Recruiting
Phase 2
Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN
Lupus Nephritis (LN)
Haisco Pharmaceutical Group Co., Ltd.105 enrolled1 locationNCT07363460
Recruiting
Phase 1Phase 2
Phase IIa Study for IPG11406 in Patients With Lupus Nephritis
Lupus Nephritis
Nanjing Immunophage Biotech Co., Ltd36 enrolled17 locationsNCT06717815
Recruiting
Phase 2
A Phase II Clinical Study on the Efficacy and Safety of SHR-2173 Injection in the Treatment of Patients With Active Lupus Nephritis
Active Lupus Nephritis
Guangdong Hengrui Pharmaceutical Co., Ltd51 enrolled1 locationNCT07229742
Recruiting
Phase 1
The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases
ANCA-associated VasculitisIgG4-Related DiseasesLupus Nephritis+1 more
Nanjing University School of Medicine24 enrolled1 locationNCT06285279
Recruiting
Phase 2
A Study of Telitacicept in Lupus Nephritis
Lupus Nephritis
RemeGen Co., Ltd.120 enrolled45 locationsNCT05680480
Recruiting
Phase 2
RY_SW01 Cell Injection Therapy in Active Lupus Nephritis
Lupus Nephritis
Jiangsu Renocell Biotech Company60 enrolled1 locationNCT06058078